Stocks · Healthcare · Medical - Pharmaceuticals
Corcept Therapeutics Incorporated CORT
$116.23 +1.93% Close, Oct 2, 2026 · NASDAQ · Market cap $12.56B
High qualityStrong trend
Next earnings report: Nov 4, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Operating margin narrowed to 0.8% from 14.2% a year earlier.
- Diluted EPS over the last four quarters was $0.42, down 62.8% year over year.
- At 276.7× trailing earnings, the shares trade at the highest P/E of the company's past five years.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Top 38%
- EPS growth (TTM, YoY)Bottom 25%
- FCF growth (TTM, YoY)Bottom 19%
- Revenue growth, 3-year CAGRTop 27%
- Revenue growth accelerationTop 20%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalTop 31%
- Gross marginTop 8%
- Operating marginTop 41%
- Cash conversion (OCF / net income)Top 31%
- Accruals (lower is better)Bottom 48%
- Net debt / EBITDA (lower is better)Top 8%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldTop 29%
- Free-cash-flow yieldTop 33%
- EBITDA / enterprise valueTop 37%
- Sales / enterprise valueBottom 24%
- P/E vs own 5-year history (lower is better)Bottom 3%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthTop 43%
- 6-month returnTop 3%
- 1-year return vs S&P 500Top 31%
- Distance from 52-week highTop 11%
- Trend checklist (0–4)Top 7%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersTop 4%
- Consecutive EPS beatsBottom 49%
- Share of analysts rating BuyBottom 19%
- Upside to consensus price targetBottom 16%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Bottom 34%
- Maximum drawdown, 3 yearsBottom 48%
- Beta vs S&P 500 (lower is better)Top 13%
- Net debt / EBITDA (lower is better)Top 8%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | 12.2% | 16.0% | ↑ |
| EPS growth (YoY) | -69.8% | -62.8% | ↑ |
| Gross margin | 98.4% | 98.3% | ↓ |
| Operating margin | 14.2% | 0.8% | ↓ |
| FCF margin | 25.2% | 12.9% | ↓ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | 16.0% | 12.2% | ↑ | Top 38% |
| EPS growth (TTM, YoY) | -62.8% | -69.8% | ↑ | Bottom 25% |
| Gross margin | 98.3% | 98.4% | ↓ | Top 8% |
| Operating margin | 0.8% | 14.2% | ↓ | Top 41% |
| Net margin | 6.6% | 18.5% | ↓ | — |
| Free-cash-flow margin | 12.9% | 25.2% | ↓ | — |
| Return on invested capital | 0.9% | — | Top 31% | |
| Revenue growth, 3-year CAGR | 23.7% | — | Top 27% |
Quality of earnings and balance sheet
- Cash conversion (OCF / net income)Above 1× means profits are backed by cash.
- 2.00×
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -6.2%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- -1.4%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- -4.0 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- -3.53×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- 0.61%
- Shareholder yield
- 0.61%
- Share count change, 1 year
- -1.7%
- Share count change, 3-year CAGR
- +2.6%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Jul 29, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 1
- Beats in the last 8 reports
- 3 of 8
- Average EPS surprise, last 4
- +100.0%
- Average 2-day reaction, last 8
- -0.5%
- Positive 20 days after report
- 4 of 8
Analysts
- Consensus price target
- $125.33
- Target vs current price
- +7.8%
- Analysts with a rating
- 26
- Share rating Buy or Strong Buy
- 54%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Jul 29, 2026 | +1383.3% | -1.3% | +16.6% | +31.2% | — |
| Apr 30, 2026 | -172.3% | -0.2% | +11.9% | +46.8% | +95.6% |
| Feb 24, 2026 | -39.4% | +3.2% | +1.8% | -4.8% | +64.7% |
| Nov 4, 2025 | -11.1% | -4.1% | +1.8% | +8.9% | -46.2% |
| Jul 31, 2025 | +26.1% | -3.9% | +0.9% | -0.3% | +4.4% |
| May 5, 2025 | +0.0% | +1.6% | -3.5% | -1.5% | -3.9% |
| Feb 26, 2025 | -29.7% | +3.5% | -8.6% | -4.8% | +23.8% |
| Oct 30, 2024 | +46.4% | -2.7% | +8.2% | +21.5% | +25.8% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Jul 29, 2026 | $0.36 | $0.02 | +1383.3% | $256.1M |
| Apr 30, 2026 | -$0.30 | -$0.11 | -172.3% | $164.9M |
| Feb 24, 2026 | $0.20 | $0.33 | -39.4% | $202.1M |
| Nov 4, 2025 | $0.16 | $0.18 | -11.1% | $207.6M |
| Jul 31, 2025 | $0.29 | $0.23 | +26.1% | $194.4M |
| May 5, 2025 | $0.17 | $0.17 | +0.0% | $157.2M |
| Feb 26, 2025 | $0.26 | $0.37 | -29.7% | $181.9M |
| Oct 30, 2024 | $0.41 | $0.28 | +46.4% | $182.5M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| P/E (trailing) | 276.7× | 30.1× | 100th | Top 29% |
| P/E (forward) | 56.4× | — | — | — |
| EV / EBITDA | 432.9× | — | — | Top 37% |
| EV / Sales | 15.00× | — | — | Bottom 24% |
| Free-cash-flow yield | 0.85% | — | — | Top 33% |
| Earnings yield | 0.36% | — | — | Top 29% |
P/E over the past five years
Range 22.0× – 221.3× since Jun 30, 2021. Each point: price on the filing date divided by trailing-twelve-month EPS known then.
What moved the stock over the past year
- Price return, 1 year
- +38.0%
- Earnings per share growth (TTM)
- -62.8%
- Change in P/E multiple
- +272.3%
Most of the move came from a change in the valuation multiple.
Technical state
Trend checklist
- ✓ Price above 20-day average
- ✓ Price above 50-day average
- ✓ Price above 200-day average
- ✓ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 133
- Days above the 200-day average
- 93
- 50-day average slope (20 days)
- +9.1%
- 200-day average slope (20 days)
- +4.9%
- Distance from 50-day average
- +2.9%
- Distance from 200-day average
- +66.2%
- RSI (14)
- 54.1
- Relative volume
- 0.55×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 64.9%
- Volatility vs own 5-year history
- 76th percentile · Normal for this stock
- Beta vs S&P 500 (2 years, weekly)
- 0.44
- Correlation with S&P 500
- 0.09
- Current drawdown from 1-year high
- -5.9%
- Maximum drawdown, 3 years
- -71.9%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Mar 31, 2025 | Mar 13, 2026 | -71.9% | 239 days | 95 days (Jul 30, 2026) |
| Feb 8, 2021 | Jan 27, 2022 | -45.9% | 245 days | 380 days (Aug 3, 2023) |
| Sep 14, 2023 | Jan 31, 2024 | -37.6% | 95 days | 87 days (Jun 5, 2024) |
| Feb 13, 2025 | Mar 6, 2025 | -26.2% | 14 days | 17 days (Mar 31, 2025) |
| Jun 6, 2024 | Jun 18, 2024 | -18.4% | 8 days | 22 days (Jul 22, 2024) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $12.56B
- P/E (TTM)
- 276.7
- EPS, diluted (TTM)
- $0.42
- Revenue (TTM)
- $830.8M
- 52-week range
- $28.66 – $126.38
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $366.0M | $401.9M | $482.4M | $675.0M | $761.4M |
| Gross profit | $360.7M | $396.5M | $475.9M | $664.2M | $748.4M |
| Operating income | $124.5M | $112.6M | $107.3M | $137.0M | $44.8M |
| Net income | $112.5M | $101.4M | $106.1M | $139.7M | $99.7M |
| EPS (diluted) | $0.89 | $0.87 | $0.94 | $1.23 | $0.82 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $182.5M | $181.9M | $157.2M | $194.4M | $207.6M | $202.1M | $164.9M | $256.1M |
| Net income | $46.7M | $30.4M | $20.5M | $35.1M | $19.7M | $24.3M | -$31.2M | $42.1M |
| EPS (diluted) | $0.41 | $0.26 | $0.17 | $0.29 | $0.16 | $0.20 | -$0.30 | $0.36 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | $167.9M | $120.3M | $127.0M | $198.1M | $142.0M |
| Capital expenditure | -$469,000 | -$413,000 | -$139,000 | -$2.2M | -$211,000 |
| Free cash flow | $167.4M | $119.9M | $126.9M | $195.9M | $141.8M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | -$296.0M | $0 | -$145.4M | -$6.0M | -$245.9M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $308.2M
- Total assets
- $888.7M
- Total liabilities
- $182.9M
- Total debt
- $9.4M
- Net debt
- -$101.6M
- Shareholders’ equity
- $705.8M
As of Jun 30, 2026 (filed Jul 29, 2026).
Short interest
- Shares sold short
- 9,350,914
- Days to cover
- 9.91
- Change vs previous report
- -0.5%
FINRA short interest, settlement date Sep 15, 2026.